Preventing Recurrent 'Idiopathic' Acute Pancreatitis Through Laparoscopic Cholecystectomy (PICUS-2)

Last updated: April 29, 2024
Sponsor: M.G. Besselink
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pancreatitis

Treatment

Laparoscopic cholecystectomy

Watchful waiting

Clinical Study ID

NCT06391359
NL82531.018.23
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Rationale: Annually, acute pancreatitis is diagnosed in 6,500 patients in the Netherlands. In up to 25% of patients no definitive cause can be determined after routine work-up including endoscopic ultrasound and this is deemed to be idiopathic acute pancreatitis (IAP). IAP is known for its high recurrence rate. It is hypothesized that microlithiasis, a type of biliary pancreatitis, is the most common cause of IAP. Laparoscopic cholecystectomy (LC) is highly effective in preventing recurrence of biliary pancreatitis. Currently no randomized trial has compared LC with conservative treatment in patients with IAP after adequate work-up including endoscopic ultrasound.

Objective: To assess the effectiveness of LC as compared to conservative treatment in patients after a first episode of 'EUS-negative' IAP.

Study design: Multicenter randomized controlled trial. Patients will be followed for one year after randomization.

Study population: Adults with a first episode of 'EUS-negative' IAP.

Intervention (if applicable): Laparoscopic cholecystectomy versus conservative treatment.

Main study parameters/endpoints: The primary endpoint is pancreatitis recurrence. Secondary endpoints include occurrence of biliary events, complications of LC, number and severity of recurrent episodes of pancreatitis, quality of life (QALY), costs (hospital and societal) and cost-effectiveness.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • At least 18 years old
  • Eligible for early (laparoscopic)* cholecystectomy
  • Full required diagnostic work-up of patient has been performed, including EUS
  • First episode of 'EUS-negative' IAP
  • Informed consent for participation was obtained *if required open cholecystectomy isallowed

Exclusion

Exclusion Criteria:

  • Recurrent acute pancreatitis
  • Diagnosis of chronic pancreatitis
  • Diagnosis of necrotizing pancreatitis
  • Current pancreatic malignancy
  • Prior cholecystectomy
  • Documented etiology of acute pancreatitis

Study Design

Total Participants: 262
Treatment Group(s): 2
Primary Treatment: Laparoscopic cholecystectomy
Phase:
Study Start date:
July 30, 2023
Estimated Completion Date:
July 30, 2026

Connect with a study center

  • Amsterdam UMC, location University of Amsterdam

    Amsterdam, Noord-Holland 1081 HV
    Netherlands

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.